神经退行性疾病的纳米抗氧化剂:一个范围审查
Muhammad Talaat1,2, Hamsa Hassan3, Ethar Ahmed Mosilhy4
1El Demerdash Hospital, Ain Shams University, Cairo, Egypt.
Discover nano
|October 29, 2025
概括
纳米药物递送系统 (NDDS) 通过改善跨血脑屏障的抗氧化剂递送来治疗神经退行性疾病 (NDDs) 是有前途的. 然而,研究主要是临床前的,纳米平台和比较研究的使用有限.
科学领域:
- 神经科学和药理学 神经科学和药理学
- 生物医学工程 生物医学工程
- 药物输送系统 药物输送系统
背景情况:
- 抗氧化剂对于神经退行性疾病 (NDD) 至关重要,但由于血脑屏障 (BBB) 的生物可用性差,它们的有效性受到限制.
- 纳米药物递送系统 (NDDS) 提供了一种有前途的策略,可以克服BBB的局限性,并增强对中枢神经系统 (CNS) 的抗氧化剂递送.
- 尽管进行了大量的临床前研究,但将NDDS的NDDS转化为临床实践仍然是一个重大挑战.
研究的目的:
- 系统地审查和总结有关NDDs纳米抗氧化剂的现有文献.
- 描述当前的研究环境,包括出版趋势和贡献机构.
- 为了确定NDDS的NDDS的研究缺口和未来调查的领域.
主要方法:
- 在PubMed上进行了全面的文献搜索,遵守PRISMA-ScR指南.
- 包括在过去五年内发表的针对NDD的纳米抗氧化剂的研究.
- 数据提取涵盖出版年,隶属,研究类型,抗氧化剂和药物输送矩阵,并分析NDDS趋势.
主要成果:
- 该分析包括171项临床前研究,有机和脂质纳米载体是最常见的输送系统.
- 纳米平台的代表性明显不足,只出现在一项研究中.
- 很少有研究 (14.04%) 使用比较设计,这表明需要更严格的研究.
结论:
- 目前对NDDS的NDDS的研究主要是临床前的,显着缺乏纳米平台应用和比较研究.
- 未来的研究应该专注于为纳米载体开发严格的验证系统和方法论方法.
- 需要制定具有成本效益的功能化纳米颗粒,以解决稳定性和无菌性问题,用于临床翻译.
更多相关视频
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
12.5K
09:02Protocol for the Differentiation of Human Induced Pluripotent Stem Cells into Mixed Cultures of Neurons and Glia for Neurotoxicity Testing
Published on: June 9, 2017
24.2K
相关概念视频
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
544
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
544
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
806
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
806
Electron Transport Chain: Complex I and II
18.4K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
18.4K
